Skip to main content
Article
Serum amyloid A and Janus kinase 2 in a mouse model of diabetic kidney disease.
PLoS One
  • Brad P Dieter, Providence Health Care, Nephrology Division, Kidney Research Institute, Spokane, Washington
  • Rick L Meek, Providence Medical Research Center, Providence Health Care, Spokane, Washington
  • Robert J Anderberg, Providence Medical Research Center, Providence Health Care, Spokane, Washington
  • Sheryl K Cooney, Providence Medical Research Center, Providence Health Care, Spokane, Washington
  • Jen L Bergin, Providence Medical Research Center, Providence Health Care, Spokane, Washington
  • Hongyu Zhang
  • Viji Nair
  • Matthias Kretzler
  • Frank C Brosius
  • Katherine Tuttle, Providence Medical Research Center, Providence Health Care, Spokane, Washington
Document Type
Article
Publication Date
1-1-2019
Abstract

BACKGROUND: Serum amyloid A (SAA), a potent inflammatory mediator, and Janus kinase 2 (JAK2), an intracellular signaling kinase, are increased by diabetes. The aims were to elucidate: 1) a JAK2-mediated pathway for increased SAA in the kidneys of diabetic mice; 2) a JAK2-SAA pathway for inflammation in podocytes.

METHODS: Akita diabetic mice (129S6) with podocyte JAK2 overexpression and angiotensin II infusion (4 weeks) were given a JAK1,2 inhibitor (LY03103801, 3 mg/kg/day orally for the last two weeks). Kidneys were immunostained for SAA isoform 3 (SAA3). SAA3 knockout and control mouse podocytes were exposed to advanced glycation end products (AGE) or exogenous SAA with JAK2 inhibition (Tyrphostin AG 490, 50μM). JAK2 activity (phosphorylation, Western blot, 1 hour) and mRNA for SAA3 and associated inflammatory genes (Cxcl5, Ccl2, and Ccl5) were measured by RT-PCR (20 hours).

RESULTS: SAA3 protein was present throughout the diabetic kidney, and podocyte JAK2 overexpression increased tubulointerstitial SAA3 compared to wild type diabetic controls, 43% versus 14% (p = 0.007); JAK1,2 inhibition attenuated the increase in SAA3 to 15% (p = 0.003). Urine albumin-to-creatinine ratio (r = 0.49, p = 0.03), mesangial index (r = 0.64, p = 0.001), and glomerulosclerosis score (r = 0.51, p = 0.02) were associated with SAA3 immunostaining scores across mouse groups. Exposing podocytes to AGE or exogenous SAA increased JAK2 activity within one hour and mRNA for associated inflammatory genes after 20 hours. JAK2 inhibition reduced SAA3 mRNA expression in podocytes exposed to AGE or SAA. SAA3 knockout podocytes had >85% lower AGE-induced inflammatory genes.

CONCLUSION: JAK1,2 inhibition reduced SAA and histological features of DKD in podocyte JAK2-overexpressing mice. In podocytes exposed to a diabetes-like condition, JAK2 inhibition reduced expression of SAA, while SAA knockout blocked expression of associated pro-inflammatory mediators. SAA may promote JAK2-dependent inflammation in the diabetic kidney.

Clinical Institute
Kidney & Diabetes
Department
Nephrology
Department
Endocrinology
Citation Information
Brad P Dieter, Rick L Meek, Robert J Anderberg, Sheryl K Cooney, et al.. "Serum amyloid A and Janus kinase 2 in a mouse model of diabetic kidney disease." PLoS One (2019)
Available at: http://works.bepress.com/katherine-tuttle/189/